Advertisement

Canadian Journal of Public Health

, Volume 100, Issue 5, pp 349–352 | Cite as

Identification of Chronic Hepatitis B and Hepatitis C Co-infection in British Columbia from 1991 to 2007

  • Lily Fang
  • Amanda Yu
  • Jane A. Buxton
Quantitative Research

Abstract

Objectives

To determine the chronic HBV/HCV co-infection identification rate in British Columbia, and examine the demographic characteristics, the order of virus identification, and trends of co-infection over time.

Methods

All newly identified cases of chronic HBV/HCV co-infection between 1991 and October 2007 were extracted from the BC integrated Public Health Information System. Differences according to sex and order of hepatitis identification were evaluated using chi-square, t-tests, and ANOVA.

Results

Of 1,815 HBV/HCV co-infected residents, 71.6% were male and the mean age at co-infection diagnosis was 40.5 years (95% CI, 40.0-41.0; range 3–85 years). Among all persons identified with HCV infection, 3.1% were identified as co-infected with HBV and 5.2% of all chronic HBV-infected were diagnosed with HCV. Annual co-infection identification rates peaked at 5.3 per 100,000 in 1996. Females were significantly younger when they were first diagnosed with a hepatitis virus (p=0.0005) at 35.2 years (95% CI, 34.0-36.5; range 3–79 years) than males at 37.9 years (95% CI, 37.0-39.7; range 4–85 years). The majority of co-infections consisted of concurrent diagnoses until 2003; since then, the number of co-infected cases identified with HBV first, HCV first and concurrent virus identification is similar.

Discussion

HBV/HCV co-infection identification rates have declined since the late 1990s, but appropriate testing and identification for both viruses are important. Some co-infection cases may be prevented through HBV vaccination and harm reduction activities for those with or at risk for HCV.

Key words

Hepatitis B hepatitis C British Columbia 

Résumé

Objectifs

Déterminer le taux de signalement des coinfections chroniques par le VHB et le VHC en Colombie-Britannique et en examiner le profil démographique, l’ordre dans lequel les virus sont signalés et les tendances des coinfections au fil du temps.

Méthode

Nous avons extrait du Système intégré d’information sur la santé publique de la Colombie-Britannique tous les cas nouvellement signalés de coinfections chroniques par le VHB et le VHC survenus entre 1991 et octobre 2007. Les écarts selon le sexe et l’ordre de signalement de l’hépatite ont été évalués à l’aide d’analyses du khi-carré, de tests t et d’analyses de la variance.

Résultats

Sur les 1,815 résidents coinfectés par le VHB et le ^VHC, 71,6 % étaient des hommes, et l’âge moyen lors du diagnostic de coinfection était de 40,5 ans (IC de 95 %, 40,0-41,0; intervalle de 3 à 85 ans). Parmi les sujets infectés par le ^VHC, 3,1 % étaient coinfectés par le VHB; 5,2 % des sujets présentant une infection chronique par le VHB avaient reçu un diagnostic d’infection par le VHC. Le taux de signalement annuel des coinfections a atteint un sommet de 5,3 p. 100 000 en 1996. À 35,2 ans, les femmes étaient significativement plus jeunes lors du premier diagnostic d’un virus de l’hépatite (p=0,0005) (IC de 95 %, 34,0-36,5; intervalle de 3 à 79 ans) que les hommes, à 37,9 ans (IC de 95 %, 37,0-39,7; intervalle de 4 à 85 ans). Jusqu’en 2003, dans la majorité des coinfections, les deux virus étaient diagnostiqués en même temps; depuis, le nombre de cas où le VHB est signalé en premier, le VHC en premier ou les deux virus en même temps est semblable.

Discussion

Les taux de signalement des coinfections par le VHB et le VHC diminuent depuis la fin des années 1990, mais il demeure important de dépister et de signaler convenablement les deux virus. Chez les sujets exposés ou infectés par le VHC, certains cas de coinfections peuvent être prévenus par le vaccin contre le VHB et par des mesures de réduction des méfaits.

Mots clés

hépatite B hépatite C Colombie-Britannique 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chuang CS, Tung SY, Lee IL, Shen CH, Wei KL, Chang TS, Wu CS. Clinical features and outcome of chronic viral hepatitis with acute exacerbation in patients with concurrent infections of hepatitis B and C virus. Dig Dis Sci 2008;53(2):511–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529–38.PubMedCrossRefGoogle Scholar
  3. 3.
    World Health Organization. The World Health Report 2003: Shaping the future. Geneva, Switzerland: WHO, 2003.CrossRefGoogle Scholar
  4. 4.
    Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 2007;21 Suppl C:5C–24C.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Heymann DL (Ed.). Control of Communicable Diseases Manual, 18th ed. Baltimore, MD: United Book Press, Inc., 2004.Google Scholar
  6. 6.
    NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19(3):1–46.Google Scholar
  7. 7.
    Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001;33(1):20–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepa-tol 1998;28(1):27–33.CrossRefGoogle Scholar
  9. 9.
    Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and “silent” HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 2001;64(3):350–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang J, Zou S, Giulivi A. Epidemiology of hepatitis B in Canada. Can J Infect Dis 2001;12(6):345–50.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Dell CA, Garabedian K. Canadian Community Epidemiology Network on Drug Use (CCENDU): 2002 National Report: Drug trends and the CCENDU network. 2003;93.Google Scholar
  12. 12.
    Kiefer LA, Honish A, Predy G, Talbot JA. The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. CMAJ 2000;162(2):207–8.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Weatherill SA, Buxton JA, Daly PC. Immunization programs in non-traditional settings. Can J Public Health 2004;95(2):133–37.PubMedGoogle Scholar
  14. 14.
    Jayaraman GC, Lee B, Singh AE, Preiksaitis JK. Trends in testing behaviours for hepatitis C virus infection and associated determinants: Results from population-based laboratory surveillance in Alberta, Canada (1998-2001). J Viral Hepat 2007;14(4):249–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Buxton J, Mehrabadi A, Preston E, Tu A. Vancouver drug use epidemiology: Site report for the Canadian Community Epidemiology Network on Drug Use. 2007;80.Google Scholar
  16. 16.
    Gully PR, Tepper ML. Hepatitis C. CMAJ 1997;156(10):1427–30.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001;165(7):889–95.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health 2004;81(1):25–37.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Calzavara L, Ramuscak N, Burchell AN, Swantee C, Myers T, Ford P, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities. CMAJ 2007;177(3):257–61.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2009

Authors and Affiliations

  1. 1.British Columbia Centre for Disease ControlVancouverCanada
  2. 2.Department of Public Health SciencesUniversity of TorontoTorontoCanada
  3. 3.School of Population and Public Health, BC Centre for Disease ControlUniversity of British ColumbiaVancouverCanada

Personalised recommendations